All In Biotech

Drug Trial Radar · NCT06059846

A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Multinational Study to Assess the Efficacy and Safety of Orally Administered Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenously Administered Imipenem-cilastatin in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

Last checked: Nov 19, 2026Latest source record: Mar 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,690 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,690

Actual

Start

Dec 21, 2023

Primary completion

Jan 27, 2025

Study completion Feb 6, 2025

Sponsor

Lead sponsor
Spero TherapeuticsIndustry
Sponsor type
Industry
Collaborators
GlaxoSmithKline
First posted
Sep 29, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to assess the efficacy of oral TBP-PI-HBr as compared with intravenous (IV) imipenem-cilastatin with respect to the overall response (combined clinical cure plus microbiological eradication) at the Test-of-Cure (TOC) visit in hospitalized adult participants (greater than or equal to (≥)18 years of age) with cUTI or AP.

Conditions

  • Urinary Tract Infection
  • Acute Pyelonephritis

Interventions

  • TBP-PI-HBrDrug

    TBP-PI-HBr film-coated immediate-release tablets.

  • Imipenem-cilastatinDrug

    Sterile powder for reconstitution administered as IV.

  • Dummy InfusionDrug

    0.9% sodium chloride administered as IV infusion.

  • Dummy TabletsDrug

    TBP-PI-HBr matching dummy tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Overall Response at the Test-of-Cure (TOC) Visit in the Microbiological Intent-to-Treat (Micro-ITT) PopulationTime frame: At Day 17 (TOC)

Locations

85 sites in 19 countries. Site status is shown where the registry gives one.

  • Medical facility

    Miami, Florida

  • Medical Facility

    Miami, Florida

  • Medical Facility

    Buenos Aires, Argentina

  • Medical Facility

    Córdoba, Argentina

  • Medical Facility

    La Plata, Argentina

  • Medical Facility

    Mendoza, Argentina

  • Medical Facility

    San Miguel de Tucumán, Argentina

  • Medical Facility

    Villa Regina, Argentina

  • Medical Facility

    Banja Luka, Bosnia and Herzegovina

  • Medical Facility

    Sarajevo, Bosnia and Herzegovina

  • Medical Facility

    Tuzla, Bosnia and Herzegovina

  • Medical Facility

    Barueri, Brazil

  • Medical Facility

    Campinas, Brazil

  • Medical Facility

    Curitiba, Brazil

  • Medical Facility

    Porto Alegre, Brazil

  • Medical Facility

    São José do Rio Preto, Brazil

  • Medical Facility

    Blagoevgrad, Bulgaria

  • Medical Facility

    Dobrich, Bulgaria

  • Medical Facility

    Gabrovo, Bulgaria

  • Medical facility

    Lom, Bulgaria

  • Medical Facility

    Pleven, Bulgaria

  • Medical Facility

    Plovdiv, Bulgaria

  • Medical facility

    Rousse, Bulgaria

  • Medical facility

    Shumen, Bulgaria

  • Medical Facility

    Sliven, Bulgaria

  • Medical facility

    Sofia, Bulgaria

  • Medical Facility

    Varna, Bulgaria

  • Medical Facility

    Čakovec, Croatia

  • Medical Facility

    Slavonski Brod, Croatia

  • Medical Facility

    Split, Croatia

  • Medical Facility

    Zagreb, Croatia

  • Medical Facility

    Kohtla-Järve, Estonia

  • Medical Facility

    Pärnu, Estonia

  • Medical Facility

    Tallinn, Estonia

  • Medical Facility

    Tartu, Estonia

  • Medical Facility

    Võru, Estonia

  • Medical facility

    Tbilisi, Georgia

  • Medical Facility

    Alexandroupoli, Greece

  • Medical Facility

    Athens, Greece

  • Medical Facility

    Ioannina, Greece

Showing 40 of 85 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.